06 May 2021: Clinical Research
Establishment and Verification of a Prediction Model for Symptomatic Radiation Pneumonitis in Patients with Esophageal Cancer Receiving Radiotherapy
Liu-Ting Yang 1ABCDEFG , Lei Zhou 1BC , Long Chen 1ACDE , Shi-Xiong Liang 1ADE , Jiang-Qiong Huang 1DEF , Xiao-Dong Zhu 12ACDEF*DOI: 10.12659/MSM.930515
Med Sci Monit 2021; 27:e930515
Table 3 Univariate analysis of clinicopathologic, dosimetric, and inflammatory parameters in predicting symptomatic radiation pneumonitis.
| Parameters | χ2 | P |
|---|---|---|
| Sex (Male vs Female) | 0.087 | 1.000 |
| Age (≤60 vs >60; years) | 0.065 | 0.799 |
| Smoking (yes vs no) | 0.120 | 0.729 |
| Smoking index ( | 0.009 | 0.926 |
| Drinking (yes vs no) | 0.042 | 0.838 |
| Location (Cervical/upper/middle/lower/multifocal) | 3.843 | 0.428 |
| T stage (T1–T2 vs T3–T4) | 2.369 | 0.228 |
| N stage (N0–N1 vs N2–N3) | 0.244 | 0.621 |
| M stage (M0 vs M1) | 1.719 | 0.340 |
| Clinical stages (I–II vs III–IV) | 0.358 | 0.809 |
| Chemotherapy (PF regimen vs TP regimen) | 2.797 | 0.094 |
| Chemotherapy cycle ( | 1.515 | 0.218 |
| Pulmonary bulla (0/1/2/3) | 2.281 | 0.516 |
| Fractional dose ( | 0.357 | 0.770 |
| MLD ( | 5.336 | 0.021 |
| V5 ( | 6.471 | 0.011 |
| V10 ( | 7.262 | 0.007 |
| V15 ( | 4.811 | 0.028 |
| V20 ( | 4.813 | 0.028 |
| V25 ( | 1.66 | 0.198 |
| V30 ( | 1.594 | 0.207 |
| V35 ( | 1.432 | 0.231 |
| V40 ( | 1.378 | 0.240 |
| NLR during RT ( | 3.824 | 0.051 |
| PLR during RT ( | 6.504 | 0.004 |
| LMR during RT ( | 5.017 | 0.025 |
| SII during RT ( | 4.477 | 0.034 |
| NLR at the end of RT ( | 11.728 | 0.001 |
| PLR at the end of RT ( | 6.370 | 0.012 |
| LMR at the end of RT ( | 9.266 | 0.002 |
| SII at the end of RT ( | 6.346 | 0.012 |
| PF – platinum-fluorouracil; TP – taxus-platinum; MLD – mean lung dose; NLR – neutrophil-to-lymphocyte ratio; RT – radiation therapy; PLR – platelet-to-lymphocyte ratio; LMR – lymphocyte-to-monocyte ratio; SII – systemic immune inflammation index. | ||